An observational study in Dyslipidemia, Angina (Stable) and Coronary Artery Disease (CAD), sponsored by Tarumanagara University. Not yet recruiting at 1 site in Indonesia. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Tarumanagara University · Observational
The goal of this observational study is to evaluate whether a contactless camera-based technology, called remote photoplethysmography (rPPG), can accurately measure cardiovascular parameters and estimate cardiovascular risk in adults aged 30 years and older living in a community setting in Semanan, Jakarta. This study aims to determine if rPPG can be used as a simple and accessible tool for early cardiovascular screening.
The main questions it aims to answer are:
Researchers will compare results obtained from rPPG-based facial video scans with results from standard medical assessments, including blood pressure measurements, heart rate evaluation, and laboratory tests for cholesterol levels, to determine the level of agreement and accuracy.
Participants will:
This study is expected to help determine whether rPPG can be used as a reliable, non-invasive, and scalable screening tool for cardiovascular risk in community and primary healthcare settings.
Introduction Remote photoplethysmography (rPPG) is an emerging contactless technology that enables extraction of physiological signals from facial video, allowing estimation of cardiovascular parameters such as heart rate and blood pressure. With the growing burden of atherosclerotic cardiovascular disease (ASCVD), early and accessible risk screening tools are essential, particularly in community settings with limited access to laboratory-based assessments. Although established risk models such as the ASCVD and Framingham scores are widely used, their application often requires clinical and laboratory data that may not be readily available. The integration of rPPG-based measurements with cardiovascular risk estimation offers a promising approach; however, its clinical validity and agreement with standard methods remain insufficiently explored .
Objective This study aims to evaluate the agreement and concordance between rPPG-derived cardiovascular parameters and standard clinical measurements, as well as to assess the alignment of rPPG-estimated ASCVD risk and Framingham heart age with conventional risk calculations.
Methods This study will use an analytical observational cross-sectional design conducted in Kelurahan Semanan, Jakarta. Adult participants (≥30 years) will be recruited through community-based sampling. Each participant will undergo clinical anamnesis, physical examination (blood pressure and heart rate), and laboratory testing (total cholesterol and HDL). In parallel, rPPG-based facial video scans will be performed under standardized conditions to obtain systolic and diastolic blood pressure, mean arterial pressure, pulse pressure, heart rate, cardiac workload, ASCVD risk, and Framingham heart age. Framingham risk will be calculated using sex-specific equations based on clinical and laboratory variables. Agreement between rPPG and standard measurements will be assessed using Bland-Altman analysis, while correlations will be evaluated using Pearson or Spearman tests. Concordance for categorical risk classification will be analyzed using Cohen's Kappa.
Expected Results It is expected that rPPG-derived heart rate will demonstrate good agreement with standard measurements, while blood pressure parameters will show moderate agreement. Additionally, rPPG-based ASCVD risk and Framingham heart age are anticipated to exhibit acceptable concordance with conventional risk calculations. These findings may support the potential role of rPPG as a preliminary screening and risk stratification tool in community-based and telemedicine settings.
The study population consists of community-dwelling adults aged 30 years and older residing in Semanan, Jakarta, Indonesia. Participants will be recruited through community-based consecutive sampling, including local residents, visitors to primary healthcare facilities, and individuals participating in community health programs. Eligible participants are those who are able to provide informed consent and undergo facial video scanning, clinical examination, and basic laboratory testing. Individuals with conditions that may interfere with rPPG signal acquisition (e.g., significant facial abnormalities), inability to remain still during measurement, severe clinical instability, or incomplete key data will be excluded. This population represents a general adult community suitable for evaluating cardiovascular risk screening tools in real-world, primary care and community settings.
Exclusion Criteria:
This cohort includes adults aged ≥30 years residing in Semanan, Jakarta, recruited through community-based sampling. Participants will undergo both index testing using remote photoplethysmography (rPPG) via facial video scan and reference standard assessments, including blood pressure measurement, heart rate evaluation, and laboratory testing (total cholesterol and HDL). Additional data such as age, sex, smoking status, and antihypertensive treatment will be collected. There is no intervention applied; all procedures are non-invasive and observational. The study aims to compare rPPG-derived cardiovascular parameters and risk estimates (ASCVD risk and Framingham heart age) with standard clinical measurements to assess agreement and validity.
Agreement of rPPG-Derived Blood Pressure with Standard Measurements
Assessment of agreement between systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and pulse pressure obtained from rPPG-based facial video analysis and standard measurements using aneroid or digital sphygmomanometers. Agreement will be evaluated using Bland-Altman analysis (mean difference and limits of agreement).
Time frame: Day 1
Agreement of rPPG-Derived Heart Rate and Cardiac Workload
Evaluation of agreement between heart rate and cardiac workload obtained from rPPG and those measured using standard methods (palpation and pulse oximetry). Agreement will be analyzed using Bland-Altman and correlation analysis (Pearson/Spearman).
Time frame: Day 1
Concordance of rPPG-Based ASCVD Risk with Standard Risk Calculation
Assessment of agreement and concordance between ASCVD risk (%) and risk categories (low, intermediate, high) estimated using rPPG and those calculated using conventional clinical and laboratory data. Concordance will be evaluated using Cohen's Kappa and correlation analysis.
Time frame: Day 1
Concordance of rPPG-Derived Framingham Heart Age
Evaluation of agreement between Framingham heart age estimated using rPPG-derived parameters and heart age calculated using standard Framingham risk equations based on clinical and laboratory variables. Agreement will be assessed using correlation and Bland-Altman analysis.
Time frame: Day 1
Plan to share: Yes — De-identified individual participant data (IPD) will be shared, including demographic variables (age, sex), clinical data (blood pressure, heart rate, smoking status, antihypertensive treatment), laboratory results (total cholesterol, HDL), and rPPG-derived parameters (systolic and diastolic blood pressure, mean arterial pressure, pulse pressure, heart rate, cardiac workload, ASCVD risk, and Framingham heart age). Derived variables such as calculated ASCVD risk scores and Framingham heart age based on standard methods will also be included. All shared data will be anonymized to remove any personally identifiable information, ensuring participant confidentiality. Supporting documents such as the study protocol, statistical analysis plan, and data dictionary will also be made available upon request.
Supporting information: Study protocol, Icf, Csr
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tarumanagara University